This technique has never before been reproduced in regular laboratory animals, unless they were manipulated or had been fed a fat-rich diet genetically. Researchers also discovered that it was feasible to reverse this process giving rats a substance that avoided cells from reading the improved levels of NPY. This substance, known as the Y1 receptor antagonist, completely avoided the NPY-induced changes, allowing rats to endure stress without raising risk for atherosclerosis.Problems with maintenance of the protein at the ulcer site , and for an adequate time period , have been identified as factors adding to this low rate of efficacy [citations omitted].’ ‘The publication of the positive safety and open label efficacy findings of our Matrix Phase 1/2 clinical research in the peer-reviewed Wound Fix and Regeneration journal has an chance of the medical community to review the significant developments that we are making in the areas of DNA-structured gene therapy and wound healing. The findings out of this Phase 1/2 clinical study are consistent with and additional supported by outcomes from our much larger blinded Phase 2b medical study as reported yesterday, which suggest that both Excellarate and its component collagen matrix known as Excellagen may actually promote wound curing at rates substantially greater than with regular of care and may have important functions as new therapeutic tools for the potential treatment of soft cells wounds such as diabetic ulcers,’ reported Christopher J.